Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial

AIMS: The phase 3 ECHO trial demonstrated superior progression-free survival (PFS) with acalabrutinib plus bendamustine-rituximab (BR) versus placebo plus BR in treatment-naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP-5862 (active metabolite) when administered with BR and evaluates exposure-response (efficacy/safety) relationships based on ECHO data. METHODS: In ECHO, patients aged ≥65 years with TN MCL received BR plus acalabrutinib or placebo. Acalabrutinib (100 mg twice daily) or placebo was administered at study start until progressive disease or unacceptable toxicity. A pooled population PK analysis dataset included 975 patients for acalabrutinib and 580 patients for ACP-5862 from ECHO plus 10 clinical trials. Exposure-response analyses examined associations between exposure and PFS, best overall response (BOR), and adverse events (AEs) from ECHO. RESULTS: Population PK analysis showed that demographics (age, body weight, sex, ethnicity, race) and other intrinsic factors (mild or moderate renal impairment; mild or moderate hepatic impairment) had no meaningful effect on acalabrutinib/ACP-5862 exposure. No impact of co-administration with BR was observed on PK exposure. Exposure-efficacy analyses of ECHO data showed a flat relationship between acalabrutinib/ACP-5862 exposure and PFS and BOR. Exposure-safety analyses of ECHO data showed no clinically meaningful correlation between acalabrutinib/ACP-5862 exposure and selected safety outcomes (grade ≥3 AEs and events of clinical interest, AEs leading to dose modifications). CONCLUSION: This analysis supports a fixed 100 mg twice daily acalabrutinib dose, in combination with BR, as well-tolerated and efficacious in treatment of patients with TN MCL.

Authors

Institutions

Publication Details

Journal
British Journal of Clinical Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.1002/bcp.70912
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial

Diansong Zhou, Shringi Sharma, Damilola Olabode, Karthick Vishwanathan et al.
British Journal of Clinical Pharmacology
Lymphoma Diagnosis and Treatment
article

Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial

Diansong Zhou, Shringi Sharma, Damilola Olabode, Karthick Vishwanathan, Simon A. Rule, Roser Calvo, Jincheng Yang, Nurahamid Siddiki
article en

Abstract

AIMS: The phase 3 ECHO trial demonstrated superior progression-free survival (PFS) with acalabrutinib plus bendamustine-rituximab (BR) versus placebo plus BR in treatment-naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP-5862 (active metabolite) when administered with BR and evaluates exposure-response (efficacy/safety) relationships based on ECHO data. METHODS: In ECHO, patients aged ≥65 years with TN MCL received BR plus acalabrutinib or placebo. Acalabrutinib (100 mg twice daily) or placebo was administered at study start until progressive disease or unacceptable toxicity. A pooled population PK analysis dataset included 975 patients for acalabrutinib and 580 patients for ACP-5862 from ECHO plus 10 clinical trials. Exposure-response analyses examined associations between exposure and PFS, best overall response (BOR), and adverse events (AEs) from ECHO. RESULTS: Population PK analysis showed that demographics (age, body weight, sex, ethnicity, race) and other intrinsic factors (mild or moderate renal impairment; mild or moderate hepatic impairment) had no meaningful effect on acalabrutinib/ACP-5862 exposure. No impact of co-administration with BR was observed on PK exposure. Exposure-efficacy analyses of ECHO data showed a flat relationship between acalabrutinib/ACP-5862 exposure and PFS and BOR. Exposure-safety analyses of ECHO data showed no clinically meaningful correlation between acalabrutinib/ACP-5862 exposure and selected safety outcomes (grade ≥3 AEs and events of clinical interest, AEs leading to dose modifications). CONCLUSION: This analysis supports a fixed 100 mg twice daily acalabrutinib dose, in combination with BR, as well-tolerated and efficacious in treatment of patients with TN MCL.

British Journal of Clinical Pharmacology
AstraZeneca (United Kingdom) (GB), AstraZeneca (United States) (US)
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon